文献速递眼底病与葡萄膜炎角膜与眼表疾病

在ClinicalTrials.gov注册的公共资助眼与视觉试验样本中的结局指标规范

Outcome Specification in a Sample of Publicly Funded Eye and Vision Trials Registered on ClinicalTrials.gov.
PubMed 文献 · JAMA Ophthalmol · 2019-01-01

该研究于2019年1月31日检索ClinicalTrials.gov中由美国国家眼科研究所资助的年龄相关性黄斑变性、干眼或屈光不正试验记录,从每个结局中提取5个规范要素。共39条记录中识别出49个独特结局域,每个结局域被记录的中位数仅1至1.5条。作者结论认为结局过多且重叠太少,呼吁就应测量哪些结局达成一致。

要点

  • 39条公共资助眼与视觉试验记录中共识别出49个独特结局域。
  • 每个独特结局域被记录的中位数(四分位距)在年龄相关性黄斑变性为1(1-3)、干眼为1.5(1-2)、屈光不正为1(1-1)。
  • 即使同一结局域在多个试验中注册,时间点、具体指标和聚合方法也存在多种指定方式。

核心结论

  • 在所检查的试验样本中,结局过多且重叠太少。
  • 不同试验测量结局的方式差异使结果难以比较,即使对于视力等成熟结局域也是如此。
  • 作者认为,为减少眼与视觉研究中的浪费,就应测量哪些结局达成一致的时机已经成熟。

研究设计与样本

  • 于2019年1月31日检索ClinicalTrials.gov中年龄相关性黄斑变性、干眼或屈光不正的临床试验记录。
  • 检索限于美国国家眼科研究所资助的试验,未设日期限制。
  • 从每条记录中每个结局提取5个规范要素:域、测量方法、指标、聚合方法和时间点。
  • 共识别39条试验记录中的49个独特结局域。

主要发现

  • 每个独特结局域被记录的中位数(四分位距)在年龄相关性黄斑变性为1(1-3)、干眼为1.5(1-2)、屈光不正为1(1-1)。
  • 即使同一结局域在多个试验中注册,时间点、具体指标和聚合方法也存在多种指定方式。
  • 在所检查的试验样本中,结局过多且重叠太少。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: For findings from clinical trials to be actionable, outcomes measured in trials must be fully defined and, when appropriate, defined consistently across trials. Otherwise, it is difficult to compare findings between trials, combine results in meta-analyses, or leverage findings collectively to inform health care decision-making. OBJECTIVE: To identify and characterize outcomes specified in ClinicalTrials.gov records for publicly funded clinical trials for 3 high-burden, high-prevalence eye conditions. DESIGN, SETTING, AND PARTICIPANTS: ClinicalTrials.gov, a registry of publicly and privately supported clinical studies, was searched on January 31, 2019, for records of clinical trials for age-related macular degeneration (AMD), dry eye, or refractive error. The search was limited to trials funded by the National Eye Institute but did not impose a date restriction. Five elements of a well-specified outcome were extracted from each outcome stated in each record, including the domain, method of measurement, metric, method of aggregation, and time points. MAIN OUTCOMES AND MEASURES: Number of outcome domains specified for trials for AMD, dry eye, and refractive error and the number of trial records specifying each unique domain. RESULTS: A total of 49 unique outcome domains specified across 39 records of trials were identified. The median (interquartile range) number of records specifying each unique outcome domain was 1 (1-3), 1.5 (1-2), and 1 (1-1) for AMD, dry eye, and refractive error, respectively. Even when the same domains were registered across multiple trials, the time point, specific metric, and method of aggregation were specified in multiple ways. CONCLUSIONS AND RELEVANCE: There were too many outcomes with too little overlap in the sample of trials that were examined. Differences in how outcomes are measured across trials make it difficult to compare results, even for well-established domains, such as visual acuity. To reduce this waste in eye and vision research, the time is ripe for agreeing on what outcomes to measure.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Le JT, Sheng K, Saldanha IJ, et al. Outcome Specification in a Sample of Publicly Funded Eye and Vision Trials Registered on ClinicalTrials.gov. JAMA Ophthalmol. 2019. PMID: 31465089. doi:10.1001/jamaophthalmol.2019.3289

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。